Thomas Pierret Selected Research

1- (N- (2- hydroxy- 5- azidobenzoyl)- 2- aminoethyl)- 4- (N- hydroxysuccinimidyl)succinate

1/2022

Immune checkpoint inhibitors and hospitalization at home in France.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Pierret Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 09/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 06/2021
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Proteinuria 09/2021
1	Vasculitis (Vasculitides) 09/2021
1	Acute Kidney Injury (Acute Renal Failure) 09/2021
1	Glomerulonephritis 09/2021
1	Hematuria 09/2021
1	Hemorrhage 09/2021

Drug/Important Bio-Agent (IBA)

1	1- (N- (2- hydroxy- 5- azidobenzoyl)- 2- aminoethyl)- 4- (N- hydroxysuccinimidyl)succinateIBA 01/2022
1	Peroxidase (Myeloperoxidase)IBA 09/2021
1	SteroidsIBA 09/2021
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 09/2021
1	Rituximab (Mabthera)FDA Link 09/2021
1	NivolumabIBA 09/2021
1	Immune Checkpoint InhibitorsIBA 09/2021
1	selpercatinibIBA 06/2021

Therapy/Procedure

2	Immunotherapy 01/2022 - 01/2022
1	Combined Modality Therapy 01/2022
1	Plasmapheresis 09/2021
1	Therapeutics 09/2021